drugset
drugset / Trial / NCT06089733

A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

NCT06089733 ↗

Phase 1 Completed 32 enrolled Abbisko Therapeutics Co, Ltd
NaSingle-groupOpen-labelTreatment

Summary

This study is a single center, open lable and fixed sequence test conducted in healthy subjects to evaluate the pharmacokinetic effects of Itraconazole and Rifampicin on a single dose of ABSK021 Oral administration. It is planned to enroll 32 healthy subjects and assign them to two parallel test groups, Part A (ABSK021 combined with Itraconazole) and Part B (ABSK021 combined with Rifampicin).

Timeline

Start
2023-04-11
Primary completion
2023-08-30
Completion
2023-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject Pimicotinib Small molecule 10 mg Oral
Subject Pimicotinib Small molecule 50 mg Oral
Subject Rifampicin Small molecule 600 mg Oral

Indications

No indication recorded.